These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969 [TBL] [Abstract][Full Text] [Related]
5. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H J Hepatol; 2024 Jul; 81(1):93-107. PubMed ID: 38403027 [TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
7. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Thimme R; Neagu M; Boettler T; Neumann-Haefelin C; Kersting N; Geissler M; Makowiec F; Obermaier R; Hopt UT; Blum HE; Spangenberg HC Hepatology; 2008 Dec; 48(6):1821-33. PubMed ID: 19003875 [TBL] [Abstract][Full Text] [Related]
9. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8 Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359 [TBL] [Abstract][Full Text] [Related]
10. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J Front Immunol; 2022; 13():923031. PubMed ID: 35924241 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. Kim KJ; Lee HW; Seong J J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056 [TBL] [Abstract][Full Text] [Related]
12. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Bei R; Mizejewski GJ Curr Mol Med; 2011 Oct; 11(7):564-81. PubMed ID: 21707514 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541 [TBL] [Abstract][Full Text] [Related]
14. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma. Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476 [TBL] [Abstract][Full Text] [Related]
16. Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice. Liu Z; Lu Z; Jing R; Zuo B; Gao X; Han G; Qi H; Wu L; Liu Y; Yin H Theranostics; 2019; 9(14):4006-4018. PubMed ID: 31281528 [TBL] [Abstract][Full Text] [Related]
17. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. Butterfield LH; Economou JS; Gamblin TC; Geller DA J Transl Med; 2014 Apr; 12():86. PubMed ID: 24708667 [TBL] [Abstract][Full Text] [Related]
18. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein. Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522 [TBL] [Abstract][Full Text] [Related]
19. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801 [TBL] [Abstract][Full Text] [Related]
20. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]